Αποτελέσματα Αναζήτησης
Rexulti User Reviews & Ratings. Rexulti has an average rating of 6.6 out of 10 from a total of 445 reviews on Drugs.com. 54% of reviewers reported a positive experience, while 26% reported a negative experience.
- 229 Reviews for Major Depressive Disorder
Rexulti for Major Depressive Disorder User Reviews. Rexulti...
- 229 Reviews for Major Depressive Disorder
Find 111 user ratings and reviews for Rexulti (brexpiprazole) on WebMD including side effects and drug interactions, medication effectiveness, ease of use and satisfaction.
27 Ιουν 2024 · Rexulti was the first medicine approved by the FDA for reducing symptoms of agitation in dementia due to Alzheimer’s disease. How Does the Medicine Work?
18 Μαΐ 2023 · Rexulti (brexpiprazole) is a once-daily oral therapy that is approved to help manage agitation — abnormal or inappropriate displays of emotion, such as shouting or shoving — associated with dementia due to Alzheimer’s disease. It was co-developed by Otsuka Pharmaceutical and Lundbeck.
12 Μαΐ 2023 · The U.S. Food and Drug Administration (FDA) this week approved the expanded use of Rexulti (brexpiprazole) for the treatment of agitation associated with dementia due to Alzheimer’s disease (AD).
The most common side effects for all indications of REXULTI include weight gain, sleepiness, dizziness, common cold symptoms, and restlessness or feeling like you need to move (akathisia). See below for more information on REXULTI clinical trials in patients with agitation that may happen with dementia due to Alzheimer's disease.
11 Μαΐ 2023 · The U.S. Food and Drug Administration (FDA) has approved Rexulti (brexpiprazole) to treat agitation associated with dementia due to Alzheimer’s disease. With this approval, Rexulti has now become the first and only therapy ever approved for this specific indication in the U.S.
